A nasty taste in the mouth

The US Federal Trade Commission (FTC) has long campaigned for pay-for-delay agreements to be presumed illegal by US courts. The blocking of a generic competitor from entering the market with a low-cost medicine through such deals has long drawn the ire of the regulatory body, which has argued that such deals are an unfair extension of a party’s patent rights.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Ligand buys biotech in $739m cash deal with litigation sweetener

28 April 2026 Pharma group strikes an all-cash transaction, combining a portfolio expansion with a contingent payment linked to a dispute over a $5 billion drug

Americas

CureVac targets Moderna with 10-patent suit over Spikevax

28 April 2026 BioNTech’s former rival—now part of its company—is seeking to assert its mRNA portfolio against Moderna in a new suit over modifications to the highly fought-over molecule.

Americas

Safeguarding critical IP in a high-risk era: WIPR Trade Secrets West 2026

28 April 2026 An event for IP, legal and compliance leaders to address the growing threat of trade secret misappropriation heads to San Jose.